PPARG and metabolic dysfunction-associated steatohepatitis: Although no drug has been approved yet for the treatment of NASH, there is clearly a role for PPAR‐γ agonists given the positive effect of pioglitazone in patients with biopsy‐proven NASH21, 22, 23, 30, 31, 32 and its incorporation into several guidelines,33, 34, 35 as well as novel PPAR‐γ agonists being tested in patients with NASH.36